Stem and progenitor cell dysfunction in human trisomies

EMBO Reports

Volumn 16, Issue 1, 2015, Pages 44-62

  Liu, Binbin ^a   Filippi, Sarah ^b   Roy, Anindita ^c   Roberts, Irene ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Down syndrome; hematopoietic stem cells; leukemia; neural progenitors; trisomy 21

Indexed keywords

BRAIN MALFORMATION; CELL AGING; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CONGENITAL HEART MALFORMATION; CRANIOFACIAL MALFORMATION; GENE DOSAGE; HEMATOPOIESIS; HUMAN; LEUKEMIA; PHENOTYPE; PHENOTYPIC VARIATION; PREMATURE AGING; PRIORITY JOURNAL; REVIEW; SELF CONCEPT; STEM CELL; TESTIS CANCER; TRISOMY 21; ANIMAL; DISEASE MODEL; DOWN SYNDROME; GENETICS; INDUCED PLURIPOTENT STEM CELL; PATHOLOGY; PHYSIOLOGY; TRISOMY;

ANIMALS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HEMATOPOIESIS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PHENOTYPE; STEM CELLS; TRISOMY;

EID: 84924987465     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201439583     Document Type: Review

References (204)

1. Morris JK, Springett A, (2014) The National Down Syndrome Cytogenetic Register for England and Wales: 2012 Annual Report. London: Public Health England
2. Rasmussen SA, Wong LC, May KM, Friedman JM, (2003) Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 111: 777-784
3. Nelson KE, Hexem KR, Feudtner C, (2012) Inpatient hospital care of children with trisomy 13 and trisomy 18 in the United States. Pediatrics 129: 869-876
4. Liang CA, Braddock BA, Heithaus JL, Christensen KM, Braddock SR, Carey JC, (2013) Reported communication ability of persons with trisomy 18 and trisomy 13. Dev Neurorehabil doi: 10.3109/17518423.2013.847980
5. Wu J, Morris JK, (2013) The population prevalence of Down's syndrome in England and Wales in 2011. Eur J Hum Genet 21: 1016-1019
6. Antonarakis SE, (1998) 10 years of Genomics, chromosome 21, and Down syndrome. Genomics 51: 1-16
7. Ross JA, Spector LG, Robison LL, Olshan AF, (2005) Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer 44: 8-12
8. Antonarakis SE, Lyle R, Dermitzakis ET, Reymond A, Deutsch S, (2004) Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 5: 725-738
9. Roper RJ, Reeves RH, (2006) Understanding the basis for Down syndrome phenotypes. PLoS Genet 2: e50
10. Bull MJ, the Committee on Genetics (2011) Health supervision for children with Down syndrome. Pediatrics 128: 393-406
11. Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, Vallance G, Perkins K, Marchi E, McGowan S, et al, (2013) GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 122: 3908-3917
12. Zigman WB, Schupf N, Sersen E, Silverman W, (1996) Prevalence of dementia in adults with and without Down syndrome. Am J Ment Retard 100: 403-412
13. Sekijima Y, Ikeda S, Tokuda T, Satoh S, Hidaka H, Hidaka E, Ishikawa M, Yanagisawa N, (1998) Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. Eur Neurol 39: 234-237
14. Holland AJ, Hon J, Huppert FA, Stevens F, (2000) Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J Intellect Disabil Res 44: 138-146
15. Tyrrell J, Cosgrave M, McCarron M, McPherson J, Calvert J, Kelly A, McLaughlin M, Gill M, Lawlor BA, (2001) Dementia in people with Down's syndrome. Int J Geriatr Psychiatry 16: 1168-1174
16. Coppus A, Evenhuis H, Verberne GJ, Visser F, van Gool P, Eikelenboom P, van Duijn C, (2006) Dementia and mortality in persons with Down's syndrome. J Intellect Disabil Res 50: 768-777
17. Lott IT, (2012) Neurological phenotypes for Down syndrome across the life span. Prog Brain Res 197: 101-121
18. Glasson EJ, Dye DE, Bittles AH, (2014) The triple challenges associated with age-related comorbidities in Down syndrome. J Intellect Disabil Res 58: 393-398
19. Hartley SL, Handen BL, Devenney DA, Hardison R, Mihaila I, Proce JC, Cohen AD, Klunk WE, Mailick MR, Johnson SC, et al, (2014) Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain 137: 2556-2563
20. Adorno M, Sikandar S, Mitra SS, Kuo A, Nicolis Di Robilant B, Haro-Acosta V, Ouadah Y, Quarta M, Rodriguez J, Qian D, et al, (2013) Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature 501: 380-384
21. Roberts I, Izraeli S, (2014) Haematopoietic development and leukaemia in Down syndrome. Br J Haematol 167: 587-599
22. Nizetic D, Groet J, (2012) Tumorigenesis in Down's syndrome: big lessons from a small chromosome. Nat Rev Cancer 12: 721-732
23. Deitz SL, Roper RJ, (2011) Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice. Genetics 189: 1487-1495
24. Ruparelia A, Pearn ML, Mobley WC, (2013) Aging and intellectual disability: insights from mouse models of Down syndrome. Dev Disabil Res Rev 18: 43-50
25. O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, Sesay A, Modino S, Vanes L, Hernandez D, et al, (2005) An aneuploid mouse strain carrying human chromosome 21 with down syndrome phenotypes. Science 309: 2033-2037
26. Gribble SM, Wiseman FK, Clayton S, Prigmore E, Langley E, Yang F, Maguire S, Fu B, Rajan D, Sheppard O, et al, (2013) Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome. PLoS ONE 8: e60482
27. Li Z, Yu T, Morishima M, Pao A, LaDuca J, Conroy J, Nowak N, Matsui S, Shiraishi I, Yu YE, (2007) Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet 16: 1359-1366
28. Yu T, Li Z, Jia Z, Clapcote SJ, Liu C, Li S, Asrar S, Pao A, Chen R, Fan N, et al, (2010) A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 19: 2780-2791
29. Yu T, Liu C, Belichenko P, Clapcote SJ, Li S, Pao A, Kleschevnikov A, Bechard AR, Asrar S, Chen R, et al, (2012) Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res 1366: 162-171
30. Raveau M, Lignon JM, Naleso V, Duchon A, Groner Y, Sharp AJ, Dembele D, Brault V, Herault Y, (2012) The App-Runx1 region is critical for birth defects and electrocardiographic dysfunctions observed in a Down syndrome mouse model. PLoS Genet 8: e1002724
31. Lopes Pereira P, Magnol L, Sahun I, Brault V, Duchon A, Prandini P, Gruart A, Bizot J-C, Chadefaux-Vekemans B, Deutsch S, et al, (2009) A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum Mol Genet 18: 4756-4769
32. Sahun I, Marechal D, Pereira PL, Nalesso V, Gruart A, Garcia JMD, Antonarakis SE, Dierssen M, Herault Y, (2014) Cognition and hippocampal plasticity in the mouse is altered by monosomy of a genomic region implicated in Down syndrome. Genetics 197: 899-912
33. Moore CS, Roper RJ, (2007) The power of comparative and developmental studies for mouse models of Down syndrome. Mamm Genome 18: 431-443
34. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM, (2009) Down syndrome- recent progress and future prospects. Hum Mol Genet 18: R75-R83
35. Lana-Elola E, Watson-Scales SD, Fisher EM, Tybulewicz VL, (2011) Down syndrome: searching for the genetic culprits. Dis Model Mech 4: 586-595
36. Das I, Reeves RH, (2011) The use of mouse models to understand and improve cognitive deficits in Down syndrome. Dis Model Mech 4: 596-606
37. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp AJ, Herault Y, (2011) Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome 22: 674-684
38. Reinholdt LG, Ding Y, Gilbert GJ, Czechanski A, Solzak JP, Roper RJ, Johnson MT, Donahue LR, Lutz C, Davisson MT, (2011) Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome 22: 685-691
39. Edgin JO, Mason GM, Spanò G, Fernández A, Nadel L, (2012) Human and mouse cognitive phenotypes in Down syndrome: implications for assessment. Prog Brain Res 197: 123-151
40. Zhang L, Fu D, Belichenko PV, Liu C, Kleschevnikov AM, Pao A, Liang P, Clapcote SJ, Mobley WC, Yu YE, (2012) Genetic analysis of Down syndrome facilitated by mouse chromosome engineering. Bioeng Bugs 3: 8-12
41. Rueda N, Florez J, Martinez-Cue C, (2012) Mouse models of Down syndrome to unravel causes of mental disabilities. Neural Plast 2012: 584071
42. Liu C, Morishima M, Jiang X, Yu T, Meng K, Kay D, Pao A, Ye P, Parmacek MS, Yu YE, (2014) Engineered chromosome-based genetic mapping establishes a 3.7 Mb critical genomic region for Down syndrome-associated heart defects in mice. Hum Genet 133: 743-753
43. Tunstall-Pedoe O, Roy A, Karadimitris A, de la Fuente J, Fisk NM, Bennett P, Norton A, Vyas P, Roberts I, (2008) Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 112: 4507-4511
44. Chou ST, Opalinska JB, Yao Y, Fernandes MA, Kalota A, Brooks JSJ, Choi JK, Gewirtz AM, Danet-Desnoyers G-A, Nemiroff RL, et al, (2008) Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 112: 4503-4506
45. Roy A, Cowan G, Mead AJ, Filippi S, Bohn G, Chaidos A, Tunstall O, Chan JKY, Choolani M, Bennett P, et al, (2012) Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA 109: 17579-17584
46. MacLean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ, Orkin SH, (2012) Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic induced pluripotent cells. Proc Natl Acad Sci USA 109: 17567-17572
47. Chou ST, Byrska-Bishop M, Tober JM, Yao Y, Vandorn D, Opalinska JB, Mills JA, Choi JK, Speck NA, Gadue P, et al, (2012) Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA 109: 17573-17578
48. Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD, (2008) Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 111: 767-775
49. Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS, (2009) Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood 113: 1929-1937
50. Alford KA, Slender A, Vanes L, Li Z, Fisher EM, Nizetic D, Orkin SH, Roberts I, Tybulewicz VL, (2010) Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood 115: 2928-2937
51. Malinge S, Bliss-Moreau M, Kirsammer G, Diebold L, Chlon T, Gurbuxani S, Crispino JD, (2012) Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest 122: 948-962
52. De Vita S, Canzonetta C, Mullighan C, Delom F, Groet J, Baldo C, Vanes L, Dagna-Bricarelli F, Hoischen A, Veltman J, et al, (2010) Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome. Oncogene 29: 6102-6114
53. Hasle H, Clemmensen IH, Mikkelsen M, (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355: 165-169
54. Hasle H, (2001) Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2: 429-436
55. Hermon C, Alberman E, Beral V, Swerdlow AJ, (2001) Mortality and cancer in persons with Down's syndrome, their parents and siblings. Ann Hum Genet 65: 167-176
56. Yang Q, Rasmussen SA, Friedman JM, (2002) Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359: 1019-1025
57. Hill DA, Gridely G, Cnattingius S, Mellemkjaer L, Linet M, Adami HQ, Olsen JH, Nyren O, Fraumeni JF Jr, (2003) Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med 163: 705-711
58. Goldacre M, Wotton CJ, Seagroate V, Yeates D, (2004) Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 89: 1014-1017
59. Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M, (2006) Cancer incidence of persons with down syndrome in Finland: a population-based study. Int J Cancer 118: 1769-1772
60. Gilbert D, Rapley E, Shipley J, (2011) Testicular germ cell tumours: predisposition genes and the male germ cell nice. Nat Rev Cancer 11: 278-288
61. Malinge S, Izraeli S, Crispino JD, (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113: 2619-2628
62. Roy A, Roberts I, Vyas P, (2012b) Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med 17: 196-201
63. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD, (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32: 148-152
64. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, et al, (2003) Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 102: 981-986
65. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A, (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 101: 4301-4304
66. Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, Mensah A, Cavani S, Dagna-Bricarelli F, Basso G, et al, (2003) Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361: 1617-1620
67. Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, Wynn R, Stevens R, Addison M, King D, et al, (2004) Natural history of GATA1 mutations in Down syndrome. Blood 103: 2480-2489
68. Hollanda LM, Lima CSP, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad STO, Costa FF, (2006) An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38: 807-812
69. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, et al, (2014) Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood 123: 70-77
70. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, Shochat C, Cazzaniga G, Biondi A, Basso G, et al, (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372: 1484-1492
71. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, et al, (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115: 1006-1017
72. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, et al, (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41: 1243-1246
73. Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, et al, (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114: 2688-2698
74. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G, Cario G, Cazzaniga G, Kulozik AE, Stanulla M, et al, (2011) Gain-of-function mutations in interleukin-7 receptor-{alpha} (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 208: 901-908
75. Tal N, Shochat C, Geron I, Bercovich D, Izraeli S, (2014) Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia. Cell Mol Life Sci 71: 365-378
76. Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, Murray A, Groet J, Giarin E, Basso G, et al, (2014) Frequent cases of Ras-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun 5: 4654-4659
77. Prasher VP, (1994) Screening of medical problems in adults with Down syndrome. Downs Syndr Res Pract 2: 59-66
78. Zana M, Szecsenyi A, Czibula A, Bjelik A, Juhasz A, Rimanoczy A, Szabo K, Vetro A, Szucs P, Varkonyi A, et al, (2006) Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun 345: 726-733
79. Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, Mortara L, Accolla RS, Nespoli L, (2012) Down syndrome, auto-immunity and T regulatory cells. Clin Exp Immunol 169: 238-243
80. McLean S, McHale C, Enright H, (2009) Hematological abnormalities in adult patients with Down's syndrome. Ir J Med Sci 178: 35-38
81. Zipursky A, (2000) Susceptibility to leukemia and resistance to solid tumors in Down syndrome. Pediatr Res 47: 704
82. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S, (2005) Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 106: 4043-4049
83. Kusters MA, Verstegen RH, Gemen EF, de Vries E, (2009) Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 156: 189-193
84. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE, (2007a) A Microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 129: 1097-1110
85. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH, (2007b) Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129: 1081-1095
86. Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, Lezeau S, Attar E, Wu JY, Lin HY, et al, (2013) Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 19: 1513-1517
87. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, et al, (2014) Leukemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506: 240-244
88. Klusmann J-H, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D, (2008) Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 111: 2991-2998
89. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO, Children's Cancer Group Study 2891 (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol 21: 3415-3422
90. Klusmann J-H, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z, (2010) Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 24: 1659-1672
91. Ng AP, Hyland CD, Metcalf D, Carmichael CL, Loughran SJ, Di Rago L, Kile BT, Alexander WS, (2010) Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood 115: 3966-3969
92. Birchler JA, (2010) Reflections on studies of gene expression in aneuploids. Biochem J 426: 119-123
93. Letourneau A, Santoni FA, Bonilla X, Sailani MR, Gonzalez D, Kind J, Chevalier C, Thurman R, Sandstrom RS, Hibaoui Y, et al, (2014) Domains of genome-wide gene expression dysregulation in Down's syndrome. Nature 508: 345-350
94. Arron JR, Winslow MM, Polleri A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, et al, (2006) NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 441: 595-600
95. Emmrich S, Rasche M, Schoening J, Reimer C, Keihani S, Maroz A, Xie Y, Li Z, Schambach A, Reinhardt D, et al, (2014) miR99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signalling. Genes Dev 28: 858-874
96. Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D, (2010b) miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 24: 478-490
97. Birger Y, Goldber L, Chlon TM, Goldenson B, Muler I, Schiby G, Jacob-Hirsch J, Rechavi G, Crispino JD, Izraeli S, (2013) Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder. Blood 122: 988-998
98. Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, et al, (2014) Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet 46: 618-623
99. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, Rainis L, Lee S, Williams O, Izraeli S, Brady HJ, (2009) ERG is a megakaryocytic oncogene. Cancer Res 69: 4665-4673
100. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, et al, (2006) Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 103: 3339-3344
101. Hussein K, Bock O, Theophile K, Schultz-Bischof K, Porwit A, Schlue J, Jonigk D, Kreipe H, (2009) MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia 23: 852-855
102. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, et al, (2013) The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 45: 1293-1299
103. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, et al, (2006) MPLW515L is a novel somatic mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3: e270
104. Carmeliet G, David G, Cassiman JJ, (1991) Cellular ageing of Alzheimer's disease and Down syndrome cells in culture. Mutat Res 256: 221-231
105. Kimura M, Cao X, Skurnick J, Cody M, Soteropoulos P, Aviv A, (2005) Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. Free Radic Biol Med 39: 374-380
106. Jacobs JJ, Lieboom K, Marino S, DePinho RA, van Lohuizen M, (1999) The oncogene and Polycomb-group gene bmi regulates cell proliferation and senescence through the ink4 locus. Nature 397: 164-168
107. Collado M, Blasco MA, Serrano M, (2007) Cellular senescence in cancer and aging. Cell 130: 223-233
108. Gil J, O'Loghlen A, (2014) PRC1 complex diversity: where is it taking us? Trends Cell Biol 24: 632-641
109. Jacobsen GK, Henriques UV, (1992) A fetal testis with intratubular germ cell neoplasia (ITGCN). Mod Pathol 5: 547-549
110. Satge D, Jacobsen GK, Cessot F, Raffi F, Vekemans M, (1996) A fetus with Down syndrome and intratubular germ cell neoplasia. Pediatr Pathol Lab Med 16: 107-112
111. Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH, (2008) Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 451: 73-75
112. Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, et al, (2009) Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459: 1126-1130
113. Yang A, Reeves RH, (2011) Increased survival following tumorigenesis in Ts65Dn mice that model Down syndrome. Cancer Res 71: 3573-3581
114. Richtsmeier JT, Baxter LL, Reeves RH, (2000) Parallels of craniofacial maldevelopment in Down syndrome and Ts65Dn mice. Dev Dyn 217: 137-145
115. Richtsmeier JT, Zumwalt A, Carlson EJ, Epstein CJ, Reeves RH, (2002) Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome. Am J Med Genet 107: 317-324
116. Trainor PA, (2005) Specification and patterning of neural crest cells during craniofacial development. Brain Behav Evol 66: 266-280
117. Roper RJ, VanHorn JF, Cain CC, Reeves RH, (2009) A neural crest deficit in Down syndrome mice is associated with deficient mitotic response to Sonic hedgehog. Mech Dev 126: 212-219
118. Trazzi S, Mitrugno VM, Valli E, Fuchs C, Rizzi S, Guidi S, Perini G, Bartesaghi R, Ciani E, (2011) APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum Mol Genet 20: 1560-1573
119. Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH, (2006) Defective cerebellar response to mitogenic Hedgehog signaling in Down's syndrome mice. Proc Natl Acad Sci USA 103: 1452-1456
120. Billingsley CN, Allen JR, Baumann DD, Deitz SL, Blazek JD, Newbauer A, Darrah A, Long BC, Young B, Clement M, et al, (2013) Non-trisomic homeobox gene expression during craniofacial development in the Ts65Dn mouse model of Down syndrome. Am J Med Genet A 161: 1866-1874
121. Matsuo I, Kuratani S, Kimura C, Takeda N, Aizawa S, (1995) Mouse Otx2 functions in the formation and patterning of rostral head. Genes Dev 9: 2646-2658
122. Degenhardt K, Rentschler S, Fishman G, Sassoon DA, (2002) Cellular and cis-regulation of En-2 expression in the mandibular arch. Mech Dev 111: 125-136
123. Sumarsono SH, Wilson TJ, Tymms MJ, Ventner DJ, Corrick CM, Kola R, Lahoud MH, Papas TS, Seth A, Kola I, (1996) Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 379: 534-537
124. Hammerle B, Lizalde C, Tejedor FJ, (2008) The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development. Eur J Neurosci 27: 1061-1074
125. Altafaj X, Dierssen M, Baamonde C, Marti E, Visa J, Guimera J, Oset M, Gonzalez JR, Florez J, Fillat C, et al, (2001) Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum Mol Genet 10: 1915-1923
126. Olson LE, Richtsmeier J, Leszl J, Reeves RH, (2004) A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 306: 687-690
127. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, Mobley WC, (2004) Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 480: 281-298
128. Hill CA, Sussan TE, Reeves RH, Richtsmeier JT, (2009) Complex contributions of Ets2 to craniofacial and thymus phenotypes of trisomic "Down syndrome" mice. Am J Med Genet A 149: 2158-2165
129. Trazzi S, Fuchs C, Valli E, Perini G, Bartesaghi R, Ciani E, (2013) The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. J Biol Chem 288: 20817-20829
130. Haydar TF, Reeves RH, (2012) Trisomy 21 and early brain development. Trends Neurosci 35: 81-91
131. Contestabile A, Fila T, Ceccarelli C, Bonasoni P, Bonapace L, Santini D, Bartesaghi R, Ciani E, (2007) cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 17: 665-678
132. Guidi S, Bonasoni P, Ceccarelli C, Santini D, Gualtieri F, Ciani E, Bartesaghi R, (2008) Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 18: 180-197
133. Guidi S, Caina E, Bonasoni P, Santini D, Bartesaghi R, (2011) Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol 21: 361-373
134. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH, (2000) Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 9: 195-202
135. Lorenzi HA, Reeves RH, (2006) Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 1104: 153-159
136. Chakrabarti L, Galdzicki Z, Haydar TF, (2007) Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci 27: 11483-11495
137. Bianchi P, Ciani E, Guidi S, Trazzi S, Felice D, Grossi G, Fernandez M, Giuliani A, Calza L, Bartesaghi R, (2010) Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 30: 8769-8779
138. Contestabile A, Fila T, Bartesaghi R, Ciani E, (2009) Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain Pathol 19: 224-237
139. Altafaj X, Martin ED, Ortiz-Abalia J, Valderrama A, Lao-Peregrin C, Dierssen M, Fillat C, (2013) Normalization of Dyrk1a expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 52: 117-127
140. Olson LE, Roper RJ, Sengstaken CL, Peterson EA, Aquino V, Galdzicki Z, Siarey R, Pletnikov M, Moran TH, Reeves RH, (2007) Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum Mol Genet 16: 774-782
141. Das I, Park JM, Shin JH, Jeon SK, Lorenzi H, Linden DJ, Worley PF, Reeves RH, (2013) Hedgehog agonist therapy corrects structural and cognitive defects in a Down syndrome mouse model. Sci Transl Med 5: 201ra120
142. Guidi S, Stagni F, Bianchi P, Ciani E, Giacomini A, De Franceschi M, Moldrich R, Kurniawan N, Mardon K, Giulani A, et al, (2014) Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. Brain 137: 380-401
143. Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E, (2014) APP-dependent alteration of GSK3β activity impairs neurogenesis in the 65Dn mouse model of Down syndrome. Neurobiol Dis 67: 24-36
144. Wechsler-Reya RJ, Scott MP, (1999) Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 22: 103-114
145. Hur EM, Zhou FQ, (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11: 539-551
146. Clark S, Schwalbe J, Stasko MR, Yarowsky PJ, Costa AC, (2006) Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 200: 256-261
147. Guedi F, Pereira PL, Najas S, Barallobre MJ, Chabert C, Souchet B, Sebrie C, Verney C, Herault Y, Arbones M, et al, (2012) DYRK1A: a master regulatory protein controlling brain growth. Neurobiol Dis 46: 190-203
148. Thomazeau A, Lassalle O, Iafrati J, Souchet B, Guedi F, Janel J, Chavis P, Delabar J, Manzoni OJ, (2014) Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a. J Neurosci 34: 1138-1147
149. Souchet B, Guedi F, Sahun I, Duchon A, Daubigny F, Badel A, Yanagawa Y, Barallaobre MJ, Dierssen M, Yu E, et al, (2014) Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage. Neurobiol Dis 69: 65-75
150. Garcia-Cerro S, Martinez P, Vidal V, Corrales A, Florez J, Vidal R, Rueda N, Arbones M, Martinez-Cue C, (2014) Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome. PLoS ONE 9: e106572
151. Ortiz-Abalia J, Sahun I, Altafaj X, Andreu N, Estivill X, Dierssen M, Fillat C, (2008) Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 83: 479-488
152. Hibaoui Y, Grad I, Letourneau A, Sailani MR, Dahoun S, Santoni FA, Gimelli S, Guipponi M, Pelte MF, Bene F, et al, (2013) Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21. PLoS Genet 9: e1003515
153. Canzonetta C, Mulligan C, Deutsch S, Ruf S, O'Doherty A, Lyle R, Borel C, Lin-Marq N, Delom F, Groet J, et al, (2008) DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet 83: 388-400
154. Hijazi M, Fillat C, Medina JM, Velasco A, (2013) Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. Exp Neurol 239: 229-234
155. Williams AD, Mjaatvedt CH, Moore CS, (2008) Characterization of the cardiac phenotype in neonatal Ts65Dn mice. Dev Dyn 237: 426-435
156. Dunlevy L, Bennett M, Slender A, Lana-Elola E, Tybulewicz VL, Fisher EM, Mohun T, (2010) Down's syndrome-like cardiac developmental defects in embryos of the transchromosomic Tc1 mouse. Cardiovasc Res 88: 287-295
157. Liu C, Morishima M, Jiang X, Yu T, Meng K, Ray D, Pao A, Ye P, Parmacek MS, Yu YE, (2014) Engineered chromosome-based genetic mapping establishes a 3.7 Mb critical genomic region for Down syndrome-associated heart defects in mice. Hum Genet 133: 743-753
158. Fuchs C, Ciani E, Guidi S, Trazzi S, Bartesaghi R, (2012) Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression. Lab Invest 92: 1648-1660
159. Conti A, Fabbrini F, D'Agostino P, Negri R, Greco D, Genesio R, D'Armiento M, Olla C, Paladini D, Zannini M, et al, (2007) Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genom 8: 268
160. Bertrand N, Roux M, Ryckebusch L, Niederreither K, Dolle P, Moon A, Capecchi M, Zaffran S, (2011) Hox genes define distinct progenitor sub-domains within the second heart field. Dev Biol 353: 266-274
161. Laforest B, Bertrand N, Zaffran S, (2014) Genetic lineage tracing of anterior Hox expressing cells. Methods Mol Biol 1196: 37-48
162. Goddeeris MM, Rho S, Petiet A, Davenport CL, Jihnson GA, Meyers EN, Klingensmith J, (2008) Intracardiac septation requires hedgehog-dependent cellular contributions from outside the heart. Development 135: 1887-1895
163. Hoffmann AD, Peterson MA, Friedland-Little JM, Anderson SA, Moskowitz IP, (2009) Sonic hedgehog is required in pulmonary endoderm for atrial septation. Development 136: 1761-1770
164. Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, Kesheti E, (2001) A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development 128: 1531-1538
165. Yuan S, Zaidi S, Brueckman M, (2013) Congenital heart disease: emerging themes linking genetics and development. Curr Opin Genet Dev 23: 352-359
166. Ackerman C, Locke AE, Feingold E, Reshey B, Espana K, Thusberg J, Mooney S, Bean LJ, Dooley KJ, Cua CL, et al, (2012) An excess of deleterious variants in VEGF-A pathway genes in Down-syndrome-associated atrioventricular septal defects. Am J Hum Genet 91: 646-659
167. Matsa E, Burridge PW, Wu JC, (2014) Human stem cells for modelling heart disease and for drug discovery. Sci Trans Med 6: 239ps
168. Jiang Y, Habibollah S, Tilgner K, Collin J, Barta T, Al-Aama JY, Tesarov L, Hussain R, Trafford AW, Kirkwood G, et al, (2014) An induced pluripotent stem cell model of hypoplastic left heart syndrome (HLHS) reveals multiple expression and functional defects in HLHS-derived cardiac myocytes. Stem Cells Trans Med 3: 416-423
169. Copplola A, Romito A, Borel C, Gehrig C, Gagnebin M, Falconnet E, Izzo A, Altucci L, Banfi S, Antonarakis SE, et al, (2014) Cardiomyogenesis is controlled by the miR99a/let-7c cluster and epigenetic modification. Stem Cell Res 12: 323-337
170. Nikolaev SI, Santoni F, Vannier A, Falconnet E, Giarin E, Basso G, Hoischen A, Veltman JA, Groet J, Nizetic D, et al, (2013) Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood 122: 554-561
171. Veitia RA, Bottani S, Birchler JA, (2013) Gene dosage effects: nonlinearities, genetic interactions, and dosage compensation. Trends Genet 29: 385-393
172. Sheltzer JM, Torres EM, Dunham MJ, Amon A, (2012) Transcriptional consequences of aneuploidy. Proc Natl Acad Sci USA 109: 12644-12649
173. Birchler JA, Veitia RA, (2012) Gene balance hypothesis: connecting issues of dosage sensitivity across biological disciplines. Proc Natl Acad Sci USA 109: 14746-14753
174. Jiang J, Jing Y, Cost GJ, Chiang JC, Kolpa HJ, Cotton AM, Carone DM, Carone BR, Shivak DA, Guschin DY, et al, (2013) Translating dosage compensation to trisomy 21. Nature 500: 296-300
175. Granese B, Scala I, Spatuzza C, Vlaentino A, Coletta M, Vacca RA, De Luca P, Andria G, (2013) Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome. BMC Med Genomics 6: 24
176. Li LB, Chang KH, Wang PR, Hirata RK, Papayannopoulou T, Rissell DW, (2012) Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11: 615-619
177. Chou CY, Liu LY, Chen CY, Tsai CH, Hwa HL, Chang LY, Lin YS, Hsieh FJ, (2008) Gene expression variation increase in trisomy 21 tissues. Mamm Genome 19: 398-405
178. Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, Bianchi DW, (2009) Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci USA 106: 9425-9429
179. Volk M, Mayer A, Lovrecic L, Luvan P, Peterlin B, (2013) Expression signature as a biomarker for prenatal diagnosis of trisomy 21. PLoS ONE 8: e74184
180. Altug-Teber O, Bonin M, Walter M, Mau-Holzmann UA, Dufke A, Stappert H, Tekesin I, Heilbronner H, Nieselt K, Reiss O, (2007) Specific transcriptional changes in human fetuses with autosomal trisomies. Cytogenet Genome Res 119: 171-184
181. Li C, Jin L, Bai Y, Chen Q, Fu L, Yang M, Xiao H, Zhao G, Wang S, (2012) Genome-wide expression analysis in Down syndrome: onsight into immunodeficiency. PLoS ONE 7: e49130
182. Loudin MG, Wang J, Leung HC, Gurusiddappa S, Meyer J, Condos G, Morrison D, Tsimelzon A, Devidas M, Heerema NA, et al, (2011) Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia 25: 1555-1563
183. McElwaine S, Mullighan C, Groet J, Spinelli M, Rinaldi A, Denyer G, Mensah A, Cavani S, Baldo C, Dagna-Bricarelli F, et al, (2004) Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol 125: 729-742
184. Xavier AC, Edawards H, Dombkowski AA, Balci TB, Berman JN, Dellaire G, Xie C, Buck SA, Matherly LH, Ge Y, et al, (2011) A unique role of Gata1s in Down syndrome acute megakaryocytic leukemia biology and therapy. PLoS ONE 6: e27486
185. Maroz A, Stachorski L, Emmrich S, Reinhardt K, Xu J, Shao Z, Käbler S, Dertmann T, Hitzler J, Roberts I, et al, (2014) GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia. Leukemia 28: 1259-1270
186. Mao R, Wang X, Spitznagel EL, Frelin LP, Ting JC, Ding H, Kim JW, Ruczinski I, Downey TJ, Pevsner J, (2005) Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol 6: R107
187. Briggs JA, Sun J, Shepherd J, Ovchinnikov DA, Chung TL, Nayler SP, Kao LP, Morrow CA, Thakar NY, Soo SY, et al, (2013) Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology. Stem Cells 31: 467-478
188. Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J, (2013) Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab 17: 132-140
189. Lockstone HE, Harris LW, Swatton JE, Wayland MT, Holland AJ, Bahn S, (2007) Gene expression profiling in the adult Down syndrome brain. Genomics 90: 647-660
190. Weick JP, Held DL, Bonadurer GF, Doers ME, Liu Y, Maguire C, Clark A, Knackert JA, Molinarolo K, Musser M, et al, (2013) Deficits in human trisomy 21 iPSCs and neurons. Proc Natl Acad Sci USA 110: 9962-9967
191. Jin S, Lee YK, Lim YC, Zheng Z, Lin XM, Ng DP, Holbrook JD, Law HY, Kwek KY, Yeo GS, et al, (2013) Global DNA hypermethylation in down syndrome placenta. PLoS Genet 9: e1003515
192. Laffaire J, Rivals I, Dauphinot L, Pasteau F, Wherle R, Larrat B, Vitalis T, Moldrich RX, Rossier J, Sinkus R, et al, (2009) Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development. BMC Genom 10: 138
193. Schuurs-Hoeijmakers JH, Vulto-van Silfhout AT, Vissers LE, van de Vondervoort II, van Bon BW, de Ligt J, Gilissen C, Hehir-Kwa JY, Neveling K, del Rosario M, et al, (2013) Identification of pathogenic gene variants in small families with intellectually disabled siblings by exome sequencing. J Med Genet 50: 802-811
194. Guihard-Costa AM, Khung S, Delbecque K, Menez F, Delezoide AL, (2006) Biometry of face and brain in fetuses with trisomy 21. Pediatr Res 59: 33-38
195. Allanson JE, O'Hara P, Farkas LG, Nair RC, (1993) Anthropometric craniofacial pattern profiles in Down syndrome. Am J Med Genet 47: 748-752
196. Hawli Y, Nasrallah M, El-Hajj Fuleihan G, (2009) Endocrine and musculoskeletal abnormalities in patients with Down syndrome. Nat Rev Endocrinol 5: 327-334
197. Patterson T, Rapsey CM, Glue P, (2013) Systematic review of cognitive development across childhood in Down syndrome: implications for treatment interventions. J Intellect Disab Res 57: 306-318
198. Margallo-Lana ML, Moore PB, Kay DW, Perry RH, Reid BE, Berney TP, Tyrer SP, (2007) Fifteen-year follow up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J Intellect Disabil Res 51: 463-477
199. Lockrow JP, Fortress AM, Granholm AC, (2012) Age-related neurodegeneration and memory loss in down syndrome. Curr Gerontol Geriatr Res 2012: 463909
200. Carroll KN, Arbogast PG, Dudley JA, Cooper WO, (2008) Increase in incidence of medically treated thyroid disease in children with Down syndrome after release of American Academy of Pediatrics Health Supervision guidelines. Pediatrics 122: e493-e498
201. Graber E, Chacko E, Regelmann MO, Costin G, Rapaport R, (2012) Down syndrome and thyroid function. Endocrinol Metab Clin North Am 41: 735-745
202. Freeman SB, Taft LF, Dooley KJ, Allran K, Sherman SL, Hassold TJ, Khoury MJ, Saker DM, (1998) Population-based study of congenital heart disease in Down syndrome. Am J Hum Genet 80: 213-217
203. Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJ, Gemke RJ, (2010) Prevalence of congenital heart disease and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 169: 1195-1199
204. Roizen NJ, Magyar CI, Kuschner ES, Sulkes SB, Druschel C, van Wijngaarden E, Rodgers L, Diehl A, Lowry R, Hyman SL, (2014) A community cross-sectional survey of medical problems in 440 children with Down syndrome in New York State. J Pediatr 164: 871-875